



Current Funding Opportunities — April 2017

**1) SBIR Phase II Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics and Prognostics toward Commercialization (R44)**  
**[\(RFA-CA-17-024\)](#)**

**SPONSOR: National Cancer Institute**

**Synopsis:** This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. Projects proposed in response to this FOA must be applicable to one of the following areas: (1) cancer therapeutics; (2) cancer imaging technologies, interventional devices and/or *in vivo* diagnostics; or (3) *in vitro* and *ex vivo* cancer diagnostics and prognostics. The purpose of this FOA is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This FOA is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services. Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required.

Application Receipt Date(s): July 6, 2017

**2) Collaborative Research Projects to Enhance Applicability of Mammalian Models for Translational Research (Collaborative R01)**  
**[\(PAR-17-244\)](#)**

**SPONSOR: National Cancer Institute**

**Synopsis:** The overarching goal of this Funding Opportunity Announcement (FOA) is to support collaborative pilot projects to generate new ideas and approaches to reduce the incidence and/or severity of auto-inflammatory or autoimmune adverse events in the setting of cancer immunotherapy. In order to facilitate formation of multidisciplinary teams with expertise in mechanisms of cancer immunology/immunotherapy as well as immune tolerance and/or autoimmunity, teams that include (a) a current NCI grantee and a current NCI grantee and a current NIAID grantee, or (b) a current NCI grantee and a current NIAMS grantee, are encouraged to propose collaborative pilot projects that utilize their complementary and synergistic expertise.

Application Receipt/Submission Date(s): Multiple dates, see announcement